SAREPTA THERAPEUTICS INC (SRPT) Fundamental Analysis & Valuation

NASDAQ:SRPT • US8036071004

17.83 USD
+0.19 (+1.08%)
Last: Mar 10, 2026, 10:22 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This SRPT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Taking everything into account, SRPT scores 3 out of 10 in our fundamental rating. SRPT was compared to 519 industry peers in the Biotechnology industry. SRPT has a bad profitability rating. Also its financial health evaluation is rather negative. SRPT has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

2

1. SRPT Profitability Analysis

1.1 Basic Checks

  • SRPT had negative earnings in the past year.
  • In the past year SRPT has reported a negative cash flow from operations.
  • In the past 5 years SRPT reported 4 times negative net income.
  • SRPT had a negative operating cash flow in each of the past 5 years.
SRPT Yearly Net Income VS EBIT VS OCF VS FCFSRPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M -400M -600M

1.2 Ratios

  • The Return On Assets of SRPT (-7.77%) is better than 84.97% of its industry peers.
  • SRPT has a Return On Equity of -20.57%. This is amongst the best in the industry. SRPT outperforms 82.66% of its industry peers.
Industry RankSector Rank
ROA -7.77%
ROE -20.57%
ROIC N/A
ROA(3y)-10.59%
ROA(5y)-13.51%
ROE(3y)-36.51%
ROE(5y)-67.48%
ROIC(3y)N/A
ROIC(5y)N/A
SRPT Yearly ROA, ROE, ROICSRPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150

1.3 Margins

  • The Gross Margin of SRPT (76.25%) is better than 83.81% of its industry peers.
  • SRPT's Gross Margin has declined in the last couple of years.
  • SRPT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 76.25%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.08%
GM growth 5Y-6.88%
SRPT Yearly Profit, Operating, Gross MarginsSRPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. SRPT Health Analysis

2.1 Basic Checks

  • SRPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • SRPT has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for SRPT has been increased compared to 5 years ago.
  • SRPT has a better debt/assets ratio than last year.
SRPT Yearly Shares OutstandingSRPT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
SRPT Yearly Total Debt VS Total AssetsSRPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.2 Solvency

  • Based on the Altman-Z score of -0.12, we must say that SRPT is in the distress zone and has some risk of bankruptcy.
  • SRPT has a Altman-Z score (-0.12) which is comparable to the rest of the industry.
  • A Debt/Equity ratio of 0.78 indicates that SRPT is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.78, SRPT is doing worse than 71.87% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF N/A
Altman-Z -0.12
ROIC/WACCN/A
WACC7.37%
SRPT Yearly LT Debt VS Equity VS FCFSRPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M 1B 1.5B

2.3 Liquidity

  • SRPT has a Current Ratio of 2.95. This indicates that SRPT is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 2.95, SRPT is not doing good in the industry: 64.55% of the companies in the same industry are doing better.
  • SRPT has a Quick Ratio of 1.79. This is a normal value and indicates that SRPT is financially healthy and should not expect problems in meeting its short term obligations.
  • SRPT has a worse Quick ratio (1.79) than 77.26% of its industry peers.
Industry RankSector Rank
Current Ratio 2.95
Quick Ratio 1.79
SRPT Yearly Current Assets VS Current LiabilitesSRPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. SRPT Growth Analysis

3.1 Past

  • SRPT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -391.67%.
  • The Revenue has grown by 15.58% in the past year. This is quite good.
  • Measured over the past years, SRPT shows a very strong growth in Revenue. The Revenue has been growing by 32.41% on average per year.
EPS 1Y (TTM)-391.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-362%
Revenue 1Y (TTM)15.58%
Revenue growth 3Y33.07%
Revenue growth 5Y32.41%
Sales Q2Q%-32.73%

3.2 Future

  • SRPT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.10% yearly.
  • Based on estimates for the next years, SRPT will show a decrease in Revenue. The Revenue will decrease by -7.26% on average per year.
EPS Next Y145.42%
EPS Next 2Y52.38%
EPS Next 3Y31.54%
EPS Next 5Y20.1%
Revenue Next Year-20.22%
Revenue Next 2Y-17.9%
Revenue Next 3Y-11.99%
Revenue Next 5Y-7.26%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
SRPT Yearly Revenue VS EstimatesSRPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B
SRPT Yearly EPS VS EstimatesSRPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 -4 -6 -8

More info and screens

Find the best growth stocksShow best growing peers

4

4. SRPT Valuation Analysis

4.1 Price/Earnings Ratio

  • SRPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • A Price/Forward Earnings ratio of 5.90 indicates a rather cheap valuation of SRPT.
  • Based on the Price/Forward Earnings ratio, SRPT is valued cheaply inside the industry as 98.65% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 24.65, SRPT is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 5.9
SRPT Price Earnings VS Forward Price EarningsSRPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SRPT Per share dataSRPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

  • SRPT's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • SRPT's earnings are expected to grow with 31.54% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.38%
EPS Next 3Y31.54%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SRPT Dividend Analysis

5.1 Amount

  • No dividends for SRPT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SRPT Fundamentals: All Metrics, Ratios and Statistics

SAREPTA THERAPEUTICS INC

NASDAQ:SRPT (3/10/2026, 10:22:49 AM)

17.83

+0.19 (+1.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-04
Inst Owners89.94%
Inst Owner Change2.76%
Ins Owners5.12%
Ins Owner Change10.03%
Market Cap1.87B
Revenue(TTM)2.20B
Net Income(TTM)-271.51M
Analysts67.27
Price Target30.93 (73.47%)
Short Float %22.39%
Short Ratio8.11
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)122.82%
Min EPS beat(2)98.8%
Max EPS beat(2)146.84%
EPS beat(4)2
Avg EPS beat(4)-38.28%
Min EPS beat(4)-376.26%
Max EPS beat(4)146.84%
EPS beat(8)6
Avg EPS beat(8)621.83%
EPS beat(12)9
Avg EPS beat(12)401.46%
EPS beat(16)10
Avg EPS beat(16)286.26%
Revenue beat(2)2
Avg Revenue beat(2)14.32%
Min Revenue beat(2)13.04%
Max Revenue beat(2)15.59%
Revenue beat(4)4
Avg Revenue beat(4)9.59%
Min Revenue beat(4)2.86%
Max Revenue beat(4)15.59%
Revenue beat(8)7
Avg Revenue beat(8)6.15%
Revenue beat(12)10
Avg Revenue beat(12)5.55%
Revenue beat(16)12
Avg Revenue beat(16)4.13%
PT rev (1m)0%
PT rev (3m)3.22%
EPS NQ rev (1m)6.15%
EPS NQ rev (3m)20.88%
EPS NY rev (1m)8.56%
EPS NY rev (3m)15.41%
Revenue NQ rev (1m)-0.1%
Revenue NQ rev (3m)3.29%
Revenue NY rev (1m)6.88%
Revenue NY rev (3m)8.34%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 5.9
P/S 0.78
P/FCF N/A
P/OCF N/A
P/B 1.42
P/tB 1.45
EV/EBITDA N/A
EPS(TTM)-6.65
EYN/A
EPS(NY)3.02
Fwd EY16.94%
FCF(TTM)-3.7
FCFYN/A
OCF(TTM)-2.33
OCFYN/A
SpS23
BVpS12.58
TBVpS12.29
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -7.77%
ROE -20.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 76.25%
FCFM N/A
ROA(3y)-10.59%
ROA(5y)-13.51%
ROE(3y)-36.51%
ROE(5y)-67.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.08%
GM growth 5Y-6.88%
F-Score2
Asset Turnover0.69
Health
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 290.01%
Cap/Sales 5.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.95
Quick Ratio 1.79
Altman-Z -0.12
F-Score2
WACC7.37%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-391.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-362%
EPS Next Y145.42%
EPS Next 2Y52.38%
EPS Next 3Y31.54%
EPS Next 5Y20.1%
Revenue 1Y (TTM)15.58%
Revenue growth 3Y33.07%
Revenue growth 5Y32.41%
Sales Q2Q%-32.73%
Revenue Next Year-20.22%
Revenue Next 2Y-17.9%
Revenue Next 3Y-11.99%
Revenue Next 5Y-7.26%
EBIT growth 1Y-206.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year193.88%
EBIT Next 3Y31.21%
EBIT Next 5Y17.55%
FCF growth 1Y19.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.6%
OCF growth 3YN/A
OCF growth 5YN/A

SAREPTA THERAPEUTICS INC / SRPT FAQ

What is the ChartMill fundamental rating of SAREPTA THERAPEUTICS INC (SRPT) stock?

ChartMill assigns a fundamental rating of 3 / 10 to SRPT.


Can you provide the valuation status for SAREPTA THERAPEUTICS INC?

ChartMill assigns a valuation rating of 4 / 10 to SAREPTA THERAPEUTICS INC (SRPT). This can be considered as Fairly Valued.


What is the profitability of SRPT stock?

SAREPTA THERAPEUTICS INC (SRPT) has a profitability rating of 2 / 10.


How financially healthy is SAREPTA THERAPEUTICS INC?

The financial health rating of SAREPTA THERAPEUTICS INC (SRPT) is 2 / 10.